True, but it's already expected Novavax will show positive earnings in Q2 filings. Sanofi partnership is not a one-off, will be followed by others. State Street Corp. just closed their 10M share short position and overall shorting is down substantially. I don't see this company becoming a nameless graveyard. If an investor requires certainty before investing, no money will ever be invested and no money will be made. I've done my DD on Novavax. It is orders of magnitude different scenario than the money I invested and risked with Todos. To each his own. Getting ever closer to recovering that Todos loss. 😎

No problem. I understand the decision to automatically dismiss any suggestion by GC because people lost money on Todos. But I think you and I can both objectively look at the potential of a company like Novavax and decide to not let our past experience get in the way of making a lot of money in an investment.

GC recommended the Novavax Covid vaccine vs the mRNA options. We take a look at the company itself. We like what we see, especially with the new CEO who is changing direction of the company and capitalizing on their world-class vaccine technologies. The Sanofi partnership validates our decision to invest. Money to be made. Todos losses becoming a blip in the life journey.

Great decision, my friend.

Sell? Are you kidding? After pretty heavy shorting driving the price lower (where I picked up a few more shares) since my last update, price is moving back up as updated Covid vaccine ships this month, positive Q2 earnings to be reported within a few weeks, and Phase 3 trial underway for new flu vaccine superior to anything currently available. Another big biotech partnering for access to Matrix-M adjuvant could be announced at any time worth billions more. $50 share price achievable in 2024, IMO. Thanks GC for steering me towards Novavax. 👍️

The Fake Analyst must not be paying attention. Maybe he's hungry, or just busy watching his MONI hopes crash yet again, to be able to monitor the TOMDF board.

Perhaps time for another round of pizza deliveries. Dominos has some specials going, one for 50% off this week, and another for Emergency Pizza. I think the Fake Analyst losing money on every investment would qualify as an EMERGENCY, don't you?





Whoever orders the pizzas... ignore the threats from the Fake Analyst that the Dominos IT team will locate you via your IP address when you log into the Dominos website. Anyone still using AOL for email is easily fooled by a fast-talking IT person. They're really not as skilled as the fake analyst believes, but I bet they could also calculate the $27 because it's "simple math."

What? If one believes what has been posted here repeatedly by pumpers, MONI has no dilution. Say it isn't so!!

State Street Corp reduces NVAX holdings by 10M shares, and concurrently % of shares shorted drops substantially. Today share price rises 8.5% on fairly heavy volume. News leak? Shorts following lead of their big dog shorter and covering their positions? Start of massive short squeeze?

FDA approval for Fall 2024 Covid vaccine due any day now.

18K shares at $5.46 average price. Holding until I see multiple big biotech partnerships and eventual buy-out. 😎. Matrix-M adjuvant is a game-changer in the vaccine world. Glad to see Novavax returning to their best game of research and development of the best vaccine technology available.

Just when we thought this company was finished trading, someone buys almost 2.7M shares.

Likely the scheme is to make posts on other message boards referencing $MONI, and spreading the rumors there. Buy a few shares to get the price moving upward, noobs see this and jump in not wanting to miss the action and get in before major news of a new acquisition, already profitable, hits the wires, all the while the pumpers here are unloading their shares to the unsuspecting noobs. Wash, Rinse, Repeat.

Anyone seen JPetro? 12 days without a single post. Probably contracted Covid yet again and is busy with his 9 specialists.

Maybe someone should send him another pizza. The crack Domino's IT team weren't much help in cracking that case. I wonder where the IP address they identified might have led them. He was so sure it would lead to me. Sorry to disappoint.



Question: If you don't recover from this bout of Covid, who gets your Amarantus shares? You know, all the AMBS shares you're still holding on advice of your attorney (as you've posted). I'm sure GC will be glad to know you're continuing to hold that large position (six figures invested) and continue to have confidence in Amarantus long-term success. 👍️ 👍️

MONI Management's Business Plan illustrated below:




MONI Investors Response to every bright, shiny new acquisition proposed by management:

NEWS: Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

https://ir.novavax.com/press-releases/2024-07-02-Novavax-Submits-Application-to-Health-Canada-for-Updated-Protein-based-2024-2025-Formula-COVID-19-Vaccine

I sold my remaining 2 AMBS shares on Friday. I made a profit on my previous sale of 600K shares, but took a small loss on this sale. 😎

I was only keeping these 2 shares so I could post here as a shareholder and empathize a bit with those with the catastrophic losses on their six-figure investment. The ones who are still posting here and still holding their shares a decade later—clearly an expression of their faith and confidence and continued hope for the ultimate success of their Amarantus Biosciences investment. One has to wonder if they're still having private phone calls with the CEO.



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167164997
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168016251

NEWS: U.S. ACIP Recommends Use of Authorized and Approved 2024-2025 COVID-19 Vaccines

https://ir.novavax.com/press-releases/U-S-ACIP-Recommends-Use-of-Authorized-and-Approved-2024-2025-COVID-19-Vaccines

June 27, 2024

Today the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of a universal recommendation for the use of 2024-2025 COVID-19 vaccines authorized under Emergency Use Authorization (EUA) or approved by Biologics License Application in individuals aged six months and older.

Novavax intends to provide doses of our 2024-2025 COVID-19 vaccine at the start of the vaccination season and upon EUA by the U.S. Food and Drug Administration (FDA). When authorized, our vaccine will be the only protein-based option available in the U.S. for individuals aged 12 and older. Non-clinical data has demonstrated broad cross-neutralizing antibodies against multiple variant strains, including JN.1, KP.2 and KP.3, indicating the potential to protect against future-drift JN.1 lineage strains.1,2 Recent public statements made by the FDA indicate that there will be no preference between JN.1 or KP.2 compositions, and both will be referred to as the 2024-2025 Formula.3

Having vaccine options is one way to potentially increase COVID-19 vaccination rates among individuals who have ceased to seek vaccination for a variety of reasons.4,5 We are working with global regulatory authorities to ensure access to our vaccine and have filed for authorization with both the U.S. FDA and the European Medicines Agency.

Use of the updated Novavax COVID-19 Vaccine, Adjuvanted in the U.S.

The updated version of the Novavax COVID-19 Vaccine, Adjuvanted targeting the JN.1 strain is currently under review by the U.S. FDA for EUA to prevent COVID-19 in individuals aged 12 and older.

It's a good thing you're still holding all of your AMBS shares, as you've posted numerous time. You'll be ready when something develops.

I sold my investment in GC's other company and rolled proceeds into another investment, where I'm already up six figures.

Thanks GC for pointing me in that direction.

Novavax’s outgoing R&D lead says future will be different for Maryland biotech

June 26, 2024

https://www.bizjournals.com/washington/news/2024/06/26/novavax-filip-dubovsky-covid-vaccine-pandemic.html

Novavax outgoing R&D head Filip Dubovsky reflects on 4 years with vaccine maker.

Dr. Filip Dubovsky was the first person to see the clinical results from Novavax’s initial Covid-19 vaccine study in 2020.

The company’s chief medical officer looked at the data on his screen — just raw numbers. He didn’t need any graphs or charts to illustrate what he already knew. He charged down the hall to tell then-CEO Stan Erck and Dr. Greg Glenn, the company’s research and development lead at the time: “Guys, we have a vaccine.”

“I’ve been at this my entire career, all I’ve done is develop vaccines — and I’ve certainly had many, many more failures than successes,” Dubovsky told me. “You can generally tell when you look at those immune responses if you have a winner or not, and there was no doubt in my mind that we had a winner the very first time I saw that data.”

Dubovsky, 59, joined Novavax (NASDAQ: NVAX) that year, as the local biotech, still licking its wounds from a near collapse, entered the race in earnest to develop a coronavirus vaccine. Until then, the Gaithersburg company had been direct competition with Dubovsky, who was at AstraZeneca, in the RSV space. But Novavax’s technology was too attractive to pass up, he said.

Dubovsky was Novavax’s chief medical officer, then became president of R&D after Glenn retired — and through that time was instrumental in the company’s voyage to get its shot to the public.

He’s stepping away now because his wife took early retirement “and there was no way in the world I was going to let her start that journey without me,” he said with a laugh. They moved to Miami Beach last month and are preparing to become nomadic, as he describes it: first traveling to Europe, then setting out on a 5,000-mile driving tour through northern Canada in their SUV.

He’ll remain an adviser to Novavax’s team — remotely — as well as a shareholder with equity input.

But his departure also makes sense, he said, because Novavax’s recent deal with Sanofi to commercialize its Covid vaccine “actually de-risked the entire game of getting this technology pushed out there,” he said, noting that up to this point, “there was uncertainty whether the company would have the wherewithal to do it.”

Dr. Filip Dubovsky is stepping away from Novavax, after a critical four years with the company.

Novavax can now shift its focus back to its R&D roots and away from commercialization.

“The company going forward is going to be very different from the one that we have right now,” Dubovsky said, reinforcing a sentiment CEO John Jacobs has conveyed since striking the Sanofi deal. “We don’t need to be spending our resources on the commercial side; we do need to be spending our resources on expanding our pipeline and developing our technology.”

Novavax is still deciding what its new structure will look like, and whether it’ll tap someone to succeed Dubovsky in the same position, or “rejig it a bit,” as he put it.

But one thing that’s clear, he said, is that Novavax’s Matrix-M adjuvant — the immune-boosting secret sauce in its Covid vaccine — can be used for much more than that.

It’s already baked into a seasonal influenza vaccine and Covid-flu combination vaccine that Novavax is testing, as well as a malaria vaccine now shipping to countries in Africa. That’s a product that only drives small revenue for the company, but uses its technology to help save kids’ lives — ironic, after Dubovsky started his career in malaria vaccines, he said. And “that’s just the tip of the iceberg,” he added.

Going forward, Novavax could dive back into the RSV arena, or develop a vaccine for bird flu — which Novavax is now exploring with the U.S. government “because it would be the obvious purchaser for such a vaccine,” Dubovsky said.

Here’s more from my conversation with Dubovsky about his four years with Novavax — about the early days, the highs and lows, and the future.

What were your first months like at Novavax, at the height of the health crisis?
Remember, those were the dark days — people weren’t allowed to come in to work. In our buildings, there were maybe four of us that would come in regularly to work. And those were very long hours, seven days a week for two years. It was also extremely engaging, because we were the underdogs. We were playing in the Super Bowl, the Stanley Cup and the Kentucky Derby all at once.

Why was that work exciting for you?
I knew the technology had promise, that it would work. We just had to get it through the hoop. And eventually we did. In a sense, the licenses we’ve gotten globally, and the use we’ve had with millions of doses, has really validated the technology. And now there’s a wide-open field that this tech can be used in.

What does the Sanofi deal mean for Novavax?
There’s no reason this technology can’t be applied to the entire portfolio of vaccines going forward. And that’s what the company hopes to do. The money we’re getting from Sanofi — we’ll be able to do that, because now we’re finally in the financial position to stabilize the company, which is stabilized, but actually start growing the portfolio.

Novavax has had some high highs and low lows. What have been the biggest challenges?
There’s no denying we were late to the party. And as far as getting our vaccine licensed — we did something that no one’s ever done before: We got licensed in a couple of years. Unfortunately, Pfizer and Moderna did it in a year and a half. And that means that they got the financial rewards from it. There were a lot of concerns about pushing forward. This company had never manufactured a commercial vaccine before, and that turned out to be a real issue.

What has the impact been?
Our vaccine is a complex biological product. That has a different regulatory path and different regulatory requirements than the mRNA vaccines. That’s why we paid the time penalty. In the end — it’s validated, it’s fully licensed in many places, it’s authorized in the U.S. And certainly, the Sanofi partnership shows the technology is developable.

What’s one standout moment as you look back?
In the early days, all the governments and people were very anxious to get a product. We would get calls from world leaders and governments on a routine basis, seeing when our vaccine would be ready, when they could access it. And that was very new for me. That was, personally, slightly intimidating for me, but also, kind of fun — because it showed the value of science, it showed society and governments and leaders really valuing science, which is something I’m a huge believer in. So it kind of validated my existence. The world was paying attention to vaccines.

NEWS: Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

https://ir.novavax.com/press-releases/2024-06-24-Novavax-Submits-Application-to-European-Medicines-Agency-for-Updated-Protein-based-2024-2025-Formula-COVID-19-Vaccine

I'll pass on your advice to Sanofi, one of the world's leading and successful biotech companies, which performed many months of due diligence on Novavax and elected to invest $1.3B in a partnership, including 4.99% ownership of outstanding NVAX shares. Yes, clearly Sanofi is wrong and they don't know what they're doing.

I must be wrong, too. I not only received the Novavax Covid vaccine (on GC's recommendation), I also did the due diligence and invested in Novavax. I bought more shares this week. I'm currently up 158% on this investment.

Feels pretty good being wrong. 😎

The WORST of Covid is gone? Not even close to being accurate. Novavax knows it. Sanofi knows it. And I know it. You have to dig deeper than lack of reporting you're seeing in the media to understand this. In any case, Novavax and Sanofi's interest in Novavax goes FAR BEYOND the Covid vaccine. That's why I'm invested and why Sanofi is invested. Again, MANY THANKS to GC for pointing me toward the excellent Novavax vaccine. 👍️

Added more NVAX shares today, bringing average share price a bit higher to $5.46.

Either trading on MONI is halted, or pumpers are unable to locate any new suckers to buy their shares. Plenty of old suckers left holding the MONI 💩 bag, continuing to chant...

MONI will deliver
BAF MONI
BUY! BUY! BUY!
Ooorah! MONI

Notice how the MONI 💩 heap keeps growing larger with each new "acquisition"? Our great grandparents saw something similar every time they used the outhouse.

        💩
      💩💩
    💩💩💩
  💩💩💩💩
💩💩💩💩💩

Novavax's New Vaccine Just Changed the Game—non-mRNA Solution

June 21, 2024
https://www.guerillastocktrading.com/novavaxs-new-vaccine-just-changed-the-game-non-mrna-solution-💉/

I haven't asked or suggested you invest in Novavax. I'm posting what I'm doing to recover my Todos investment losses. If someone does the same, that decision is on them, not me. It's a hard concept to grasp for some here who choose to blame everyone else for their failures. So far I'm winning BIG with Novavax as an investment, and have no doubt I'll recover every dollar lost from Todos (and much more).

GC didn't recommend Novavax as an investment. He recommended the Novavax Covid vaccine, which I investigated thoroughly and received in Fall 2023. My due diligence into the vaccine led me to discover a company with a new CEO with a solid plan to turn the company into a powerhouse biotech. I was impressed with their technology and his vision for returning the focus of the company to what they do best, which is R&D. I would probably have not considered them as an investment had it not been for Gerald's strong recommendation of their vaccine on Twitter/X and in private emails. So, yes, I give him credit for steering me towards the investment opportunity. And the Sanofi partnership validated the CEO's plan and my due diligence into the company. More big biotech partnerships to follow, sending share price much higher.

So, you will stick to the mRNA-based Covid vaccines if you choose to get vaccinated, and NOT the Novavax vaccine that's superior in every aspect (efficacy, longevity, and safety) just because GC recommended it. Smart move. Sounds like a decision the Fake Analyst would make too. Hopefully you haven't invested in any of the 💩 he's invested in or recommended.

Novavax plans to have the doses of JN.1 version of its protein-based Covid-19 vaccine, NVX-CoV2705, for individuals aged 12 years and above ready for distribution in the US by mid-July 2024. Their FDA application was submitted last week, and is awaiting approval under EUA. They are ahead of both Pfizer and Moderna this year in availability date to the public, with efficacy, longevity of protection, and a safety profile that exceeds all mRNA Covid vaccine options.

Added more NVAX shares on the dip today, bringing average share price a bit higher to $5.37, with 96.3% of my shares purchased prior to the Sanofi partnership. 😎

Expecting to make an absolute killing on this stock over the next few years. Thanks to GC for turning me onto Novavax.

I'll post occasional updates for JPetro since he's a big fan of our former CEO, part of the inner circle that refer to him as "Gerry" while the rest of us call him Gerald. Perhaps I'll be lucky enough to get a dozen or so "CONGRATULATIONS" when I pass the milestone for recovering my Todos Medical losses with the NVAX investment. 👍️

Added more NVAX shares on the dip today, bringing average share price a bit higher to $5.37, with 96.3% of my shares purchased prior to Sanofi partnership. 😎

Expecting to make an absolute killing on this stock over the next few years. Thanks to GC for turning me onto Novavax.

MONI NEWS!!

So why would ANY company that has passed the grueling scrutiny of the U.S. government want to hook up with MONI? That would raise some serious concerns from those same investigators who conducted due diligence for said company and would likely sour their outlook on that company. All they need to do is look at MONI's reputation for pumping events that never come to completion. That would raise serious red flags, except of course for those who is trapped in their investment here at much higher share prices and cannot be objective.

Get real. Not happening.

Other people are "posting" they are buying. If one is trying to dump their shares, they aren't going to actually buy shares while the price is moving higher. The shares they're trying to unload are already bought. Buy low and sell high (to the bigger suckers).

When challenged on another board about my reported buys or holdings, I was able to post clippings from my Fidelity account to prove what I posted. That's not the case here. Buyers beware of those pumping this 💩 over the past decade. Why are they still here? Conclusion: There must be an endless stream of "bigger suckers".

Novavax, Inc. (NASDAQ:NVAX) has caught the attention of institutional investors who hold a sizeable 49% stake

SimplyWallStreet.com
June 10, 2024

https://finance.yahoo.com/news/novavax-inc-nasdaq-nvax-caught-121817276.html

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Zacks Equity Research
June 10, 2024

https://finance.yahoo.com/news/investors-heavily-search-novavax-inc-130016966.html

The Motley Fool: Bull Market and Beyond: 3 Stocks Just Waiting to Soar
June 11, 2024

https://www.fool.com/investing/2024/06/11/bull-market-and-beyond-3-stocks-that-may-soar/

Novavax is listed as #1 stock.

Annual Shareholders Meeting to be held Thursday, June 13, 2024 @ 08:30 a.m. Eastern. Links below.

2024 Proxy Statement

Virtual Shareholder Meeting

Your boy JPET is approaching 12 years on the MONI board. #NUFFSAID



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=81637191

BTMLRP Update - 6/9/24

Link to transcript of Novavax Jeffries 2024 Global Healthcare Conference

https://stkt.co/M9gyc5AQ

Worth reviewing the call again in transcript format. Transcripts give one the ability to search for specific items or keywords. Enjoy!!

The "criminals" you refer to were invested here and lost money too. I stand by my decision to invest in a company that had actual products on the market generating sales, millions in revenue from their Provista lab, and actual SEC filings that documented all this.

You can call it a pump and dump if you want, but the objective of being invested and conspiring with other in a pump and dump is to make money, no? So how did these "criminals" fair on that goal? Those of us who accumulated shares over several years and held to the end lost most or all of their investment. Yay for us!! We really screwed over everyone. Some here follow the lead of your beloved "JPET" and blame others for their decision to invest here.

Last time I checked Google works for everyone, which enables every investor to do their own due diligence and not just follow the actions of some total strange posting on a message board. I have posted hundreds, if not thousands of links to support my opinions posted here. If someone reads my post and decides to invest, that decision is on them, not the poster. I know that concept if foreign to a lot of people today. You and "JPET" are among them.

Todos had a bright "potential" future but it was always a high-risk investment. Most small startups fail. That's well documented. It's unfortunate things didn't work out because Todos had products that ACTUALLY helped people. Tollovid helped me and thousands of others, and is still being used by medical professionals in Long Covid centers. In a small clinical trial of moderate to severe hospitalized Covid patients, Tollovir had a 100% recovery rate, where 23% of the patients receiving standard-of-care Remdesivir DIED. One woman's condition was so severe she was on a respirator (and it's well documented how those patients fare) and had to receiver the Tollovir dissolved in liquid and administered through a feeding tube. Another patient's condition was so severe doctors were considering the dangerous process of infusing oxygen directly into her bloodstream to try to save her life, and after administering Tollovid she made a full recovery. So don't tell me this was a pump and dump company, you ignorant f*ck. Posting such claims shows those of us invested here just how naive and uninformed you are about Todos Medical.

If you want to see a real pump and dump, take a look at a company your "JPET" friend has been invested in and pumping for over a decade, starting his initial investment at 30 cents and which currently trades well below 1 cent. A company that has changed it's name multiple times during that period, has the bare minimum of SEC filings, and the ones that are filed look like they were created on Word 1998 Edition, and who keep their investors "informed" and "pumped up" with social media posts that claim things that never seem to materialize. This meets the classic definition of a pump and dump scheme, one which you and "JPET" are aggressively supporting with your posts.

For example, they dangled a product called BitGift that was going to change the cryptocurrency world but never generated a dime of revenue, was eventually sold, and yet those sales proceeds don't appear on any SEC filing. A clue to the carrot-and-stick potential of BitGift should have been their website where Crypto was spelled CRYTPO for months before it was corrected, many instances of incorrect grammar, and repeating the same sentences multiple times. And then there was the acquisition of gold mines in Peru that was actually reported as completed in the news, and a month later suddenly dematerialized and wasn't spoken about again. I will only mention the private aerospace company that was reported close to being acquired, with tens of millions of revenue, yet faded away.

Redspeed has compiled a long list of accurate discrepancies for that company's claims and falsehoods and posted it there. A real high-quality company to invest in, yessir. Yet you post on that board and support that POS company and call Todos a pump and dump. LMAO

BREAKING: 9th Circuit Court of Appeals Rules mRNA COVID-19 Jab is NOT a Vaccine Under Traditional Medical Definitions
by Jim Hoft
June 8, 2024

https://www.thegatewaypundit.com/2024/06/breaking-9th-circuit-court-appeals-rules-mrna-covid/

The United States Court of Appeals for the Ninth Circuit has delivered a seismic decision that could reshape public health policy across the nation.

In a contentious case involving the Health Freedom Defense Fund and other plaintiffs versus the Los Angeles Unified School District (LAUSD), the court has declared that mRNA COVID-19 injections do not qualify as vaccines under traditional medical definitions.

The case revolved around the LAUSD’s COVID-19 vaccination policy, which required all employees to be fully vaccinated against COVID-19 by a specified deadline.

The plaintiffs argued that the district’s vaccine mandate infringed upon their fundamental right to refuse medical treatment, as the mRNA injections do not prevent the transmission of COVID-19 but merely mitigate symptoms for the recipient.

The court’s opinion, penned by Circuit Judge R. Nelson and supported by Judge Collins, asserts that the mRNA shots, marketed as vaccines, do not effectively prevent the transmission of COVID-19 but merely reduce symptoms in those who contract the virus. This crucial distinction undermines the foundational premise of the vaccine mandates enforced by various governmental and educational institutions.

Judge Nelson pointed out that the mandate was inconsistent with the Supreme Court’s century-old ruling in Jacobson v. Massachusetts, a case that upheld the state’s right to enforce smallpox vaccinations due to their proven effectiveness in preventing disease spread. In contrast, the mRNA COVID-19 shots do not offer such public health benefits, thus failing the criteria established by Jacobson.

The ruling points out that traditional vaccines are designed to provide immunity and prevent transmission, which is not conclusively proven in the case of mRNA COVID-19 shots.

The Gateway Pundit previously reported that the Centers for Disease Control and Prevention (CDC) had modified the definition of “vaccine” to include the mRNA shots.

So, look at what the CDC did. Here’s the definition the CDC used on 26 August 2021:

• Vaccine– “a product that stimulates a person’s immune system to produce immunity to a specific disease.”
• Vaccination– “the act of introducing a vaccine into the body to produce immunity to a specific disease.”

Rather than admit the COVID-19 vaccine is not working as advertised, the CDC took a page out of Orwell’s 1984 and opted for new spin language.

Here is the new definition:

• Vaccine– “a preparation that is used to stimulate the body’s immune response against diseases.”

It can be recalled that Pfizer’s President of International Developed Markets, Janine Small, admitted in an EU hearing that the vaccine had never been tested on its ability to prevent transmission, contrary to what was previously advertised.

Judge Collins, in a concurring opinion, highlighted that compulsory medical treatments for individual health benefits infringe upon the fundamental right to refuse such treatments. This perspective aligns with the constitutional principles protecting personal liberty against unwarranted governmental intrusions.

You can read the full ruling at the link below:

Ruling No. 22-55908

NEWS: Novavax gets grant for vaccine for treating or preventing c. difficile bacterial infection

https://www.pharmaceutical-technology.com/data-insights/novavax-gets-grant-for-vaccine-for-treating-or-preventing-c-difficile-bacterial-infection/?cf-view

June 7, 2024

Novavax has developed a vaccine composition to treat or prevent C. difficile infection. The multivalent immunogenic polypeptide contains portions of multiple toxins from bacteria, inducing effective immune responses. The patent aims to provide innovative methods for combating bacterial infections.

According to GlobalData’s company profile on Novavax, Anti-RSV vaccines was a key innovation area identified from patents. Novavax's grant share as of April 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11938179B2) discloses a multivalent immunogenic polypeptide designed to target Clostridium difficile infections. The polypeptide consists of a binary toxin (CDT) portion, a Toxin A portion, and two Toxin B portions, each derived from a C. difficile toxin protein. The patent specifies the amino acid sequences for each portion, emphasizing a high degree of homology to specific sequences (at least 90%, 95%, 97%, 98%, or 99% homology). The arrangement of the portions, with the Toxin A portion positioned between the two Toxin B portions, and the presence of specific amino acid linkers between them, are also detailed in the claims.

Moreover, the patent covers a nucleic acid molecule encoding the polypeptide, along with a method for its preparation involving expression in an insect host cell and isolation using a non-ionic detergent. An immunogenic composition comprising the polypeptide and a suitable carrier, excipient, or diluent is also described, with the inclusion of an adjuvant, particularly a saponin-based adjuvant containing specific fractions in defined proportions. This patent highlights a novel approach to developing an immunogenic polypeptide targeting C. difficile infections, with a focus on specific amino acid sequences, arrangement, and production methods, offering potential advancements in combating this challenging medical condition.

Be careful with those videos. The dancing black maid has already been proven to give someone here a woodie. Same someone who posts hundreds of pics of Gerald over the years. Obsession at it's finest, on public display. 🥰

Did you invest in Gerald's recommended biotech, Red? I know you were thinking about it. Even with the profit taking and shorting over last 2 sessions, I'm still up 240% (over $227K). Still on my way to recovering all of my Todos losses. 💰️💵 It's well documented on multiple boards when I started investing there 8 months ago, and rolled over all of my Todos exit proceeds into that stock back in February. Fantastic position to be in with this stock... millions in revenue coming in already, billions starting in 2025. Almost all of my current holdings were purchased prior to the Sanofi partnership. 😎 Unlike some penny stocks (MONI), this company doesn't pre-announce a partnership until the deal is signed and SEC documents filed in conjunction with the news release.



Sure beats playing with the same penny stocks for over a decade hoping for a zip code change, as well as having the well-known CEO love/hate dichotomy to deal with. Perhaps some of those 9 specialists have a minor in Psychology and could help calm any emotional issues with unrequited love and feelings of abandonment.

I wonder how much the fake analyst is up on IBIO and MONI.

"oo-rah" – 🤣

Comments on today's conference presentation by Alexis on Yahoo.

Go ahead, just mention the poster on ST. My Yahoo login was cancelled from lack of use.

Good summary of today's conference call posted by dennissan on ST. I was on the call and agree 100%. The oncology mention was new info. I am extremely bullish on future of Novavax. 👍️